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Background. We have earlier reported that amio-
darone, a potent and commonly used antiarrhyth-
mic drug increases serum desmosterol, the last
precursor of cholesterol, in 20 cardiac patients by
an unknown mechanism.
Objective. Here, we extended our study to a large
number of cardiac patients of heterogeneous diag-
noses, evaluated the effects of combining amio-
darone and statins (inhibitors of cholesterol
synthesis at the rate-limiting step of hydroxy-
methyl-glutaryl CoA reductase) on desmosterol
levels and investigated the mechanism(s) by which
amiodarone interferes with the metabolism of
desmosterol using in vitro studies.
Methods and Results. We report in a clinical case–control
setting of 236 cardiac patients (126 with and 110
without amiodarone treatment) that amiodarone
medication is accompanied by a robust increase in
serum desmosterol levels independently of gender,
age, body mass index, cardiac and other diseases,
and the use of statins. Lipid analyses in patient
samples taken before and after initiation of amio-
darone therapy showed a systematic increase of
desmosterol upon drug administration, strongly
arguing for a direct causal link between amiodarone
anddesmosterol accumulation.Mechanistically,we
found that amiodarone resulted in desmosterol
accumulation in cultured human cells and that the
compound directly inhibited the 24-dehydrocholes-
terol reductase (DHCR24) enzyme activity.
Conclusion. These novel findings demonstrate that
amiodarone blocks the cholesterol synthesis path-
way by inhibiting DHCR24, causing a robust
accumulation of cellular desmosterol in cells and
in the sera of amiodarone-treated patients. It is
conceivable that the antiarrhythmic potential and
side effects of amiodarone may in part result from
inhibition of the cholesterol synthesis pathway.
Keywords: amiodarone, desmosterol, DHCR24, c-
holesterol biosynthesis, cholesterol absorption.
Introduction
Amiodarone has been used clinically for more than
half a century and is the most commonly used
potent antiarrhythmic drug to suppress atrial and
ventricular tachyarrhythmias [1]. It acts through
multiple mechanisms, including prolongation of
repolarization, reduction of excitability and slowing
of conduction [2]. It is an iodinated derivative of
benzofuran and is metabolized in the liver to an
active metabolite desethylamiodarone (DEA).
Amiodarone has a very long half-life of approxi-
mately 60 days and has several adverse effects,
adding up to 15% during the first year of treatment†Contributed equally.
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and up to 50% during long-term use [1]. The most
serious adverse effects are pulmonary and hepatic
toxicity and abnormalities in thyroid function. The
benzofuran ring is highly lipophilic, resulting in
effective distribution of the drug into different
organs and cells, where the drug is assumed to
cause structural and functional disturbances, a
‘lipid traffic jam’ [3,4]. It is not clear whether the
amiodarone-induced lipid accumulation induces
the organ toxicities described during amiodarone
treatment.
We have earlier described in a limited number of
cardiac patients with myocardial inflammatory
disease (i.e. 20 patients with cardiac sarcoidosis
or giant cell myocarditis) that amiodarone affected
cholesterol biosynthesis [5]. An unexpected finding
in amiodarone-treated patients was that the con-
centration of serum desmosterol, the last precursor
of cholesterol in the Bloch unsaturated sterol side
chain pathway, was increased on average 12-fold
compared with the control subjects [5]. The mech-
anism by which amiodarone increases circulating
desmosterol is not known [6]. However, desmos-
terol can regulate inflammatory responses [7],
raising the possibility that the observed desmos-
terol accumulation upon amiodarone treatment in
this study was somehow related to inflammatory
cardiac diseases.
The aim of the present study was to evaluate in
a clinical case–control setting if the amiodarone-
induced increase in serum desmosterol levels
can be reproduced in a large and heterogeneous
group of cardiac patients excluding inflamma-
tory myocardial disease, and whether it depends
on gender, age, body mass index (BMI) or
different diseases. In addition, we evaluated
whether the inhibition of hydroxy-methyl-glu-
taryl CoA reductase (HMGCR) by statins inter-
fered with the amiodarone-induced effects on
cholesterol precursors and whole-body choles-
terol metabolism. Finally, we investigated the
detailed mechanism(s) by which amiodarone
interfered with the metabolism of desmosterol
using in vitro studies.
Materials and methods
Clinical study population
The study population consisted of 236 consecutive
cardiac patients, 174 men and 62 women with a
mean age of 61  1 (SE) years, who were referred to
the Department of Cardiology, Helsinki University
Hospital in the years 2018–2019 because of vari-
ous cardiac problems. Of these patients, we
selected 126 consecutive subjects who were on
long-term amiodarone treatment for severe
arrhythmias (amiodarone group), and 110 age-
and sex-matched controls without amiodarone
treatment (control group). The primary cardiac
diagnoses in the control group were matched as
much as possible with those of the amiodarone
group. Amiodarone and lipid-lowering treatment
had to be unchanged for at least eight weeks before
the study. In-hospital patients were studied when
they had reached a stable state of health. All
subjects gave their written informed consent. The
study was performed according to the principles of
the Declaration of Helsinki. The Ethics Committee
for the Department of Medicine, Hospital District of
Helsinki and Uusimaa approved the study
protocol.
Clinical study design
Blood samples were drawn after a 12-h fasting.
The subjects were weighed and their height was
measured, BMI was calculated as weight (kg)/
height (m)2, and clinical data including medical
history and symptoms, laboratory tests (especially
alanine aminotransferase and total or free T4),
and current drug treatments were recorded. The
in-hospital subjects were studied on the standard
hospital diet and outpatients on their normal
habitual diet.
Clinical study methods
Serum cholesterol and noncholesterol sterols
zymostenol (called cholestenol in our previous
study) [5], desmosterol, lathosterol and squalene
(i.e. cholesterol precursors), and campesterol,
sitosterol, stigmasterol and avenasterol (i.e. plant
sterols), and cholestanol (5a-saturated derivative of
cholesterol) were analysed using gas–liquid chro-
matography (GLC) with a 50-m capillary column
(Ultra 2, Agilent Technologies, Wilmington, DE)
and flame ionization detection with 5a-cholestane
as internal standard [8]. The identities of the sterol
peaks were further verified by mass spectrometry
[5]. Serum concentrations of the noncholesterol
sterols and squalene were adjusted to cholesterol
in the same GLC run and expressed as ratios to
cholesterol (102 µmol mmol1 cholesterol) in order
to enable their comparison between subjects and
populations with different serum cholesterol levels.
Therefore, serum noncholesterol sterols are given
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as ratios to cholesterol herein. Serum triglyceride
concentrations were analysed enzymatically using
an automated analyser (Thermo Fisher Scientific
IndikoTM).
Sterol measurements in A431 cells
A431 cells (ATCC, cat. no. CRL-1555) were cul-
tured in DMEM (Lonza), supplemented with 10%
(v/v) FBS, penicillin/streptomycin (100 U mL1
each), L-glutamine (2 mmol L1) at 37°C in 5%
CO2. Mycoplasma testing was performed regularly
using PCR detection. The 24-dehydrocholesterol
reductase (DHCR24) knockout (KO) A431 cell line
was generated with CRISPR/Cas9 technology.
Briefly, cells were transfected with Cas9 nickase
plus a pair of sgRNAs (target sites: DHCR24-1A,
AGGGCGCCCCGTGCACATGA AGG and DHCR24-
1B: TCACTGTCTCACTACGTGTC GGG) [9]. Single
clones were isolated as described [10], and clones
lacking DHCR24 were identified by Western blot-
ting using an anti-DHCR24 antibody (Santa Cruz,
D-10, 1:500). For sterol measurements, cells were
delipidated by culturing in serum-free medium
supplemented with 5% lipoprotein-deficient serum
for 3 days and treated with amiodarone (Cayman,
15213), N-desethylamiodarone DEA (Cayman,
9000537) or solvent (DMSO) only for the final
48 h. Cells were washed, scraped into ice-cold PBS
and pelleted. Protein concentrations were mea-
sured using the Bio-Rad DC assay. Lipids were
extracted with chloroform–methanol, saponified
with potassium hydroxide in ethanol, extracted
with hexane and silylated with trichloromethylsi-
lane. Sterols (cholesterol, lanosterol, zymosterol,
zymostenol and desmosterol) were separated and
quantified by capillary GLC as described above.
DHCR24 activity assay
CHO-DHCR24-V5 cells were cultured in DMEM/
F12 media, supplemented with 5% (v/v) lipopro-
tein-deficient serum, 150 lg mL1 hygromycin B
[11]. Cells were plated and grown for 24 h before
treating with DMSO, amiodarone (Sigma-Aldrich,
A8423) or triparanol (Cayman, 20918) for 48 h.
During the final 4 h of the treatment, cells were
treated with [2H6]-desmosterol complexed to
methyl-b-cyclodextrin, followed by lipid extraction
and derivatization with N,O-Bis(trimethylsilyl)tri-
fluoroacetamide for GC-MS analyses. The m/z
values for the ions detected in selective ion mon-
itoring mode are as previously detailed (11): 5a-
cholestane: m/z = 217.30, 372.4, D6-cholesterol:
m/z = 374.41, 464.6, D6-desmosterol: m/
z = 333.24, 462.43.
To assay for DHCR24 enzyme activity in vitro, we
isolated crude microsomes from CHO-DHCR24-V5
cells. CHO-DHCR24-V5 cells were plated and
grown in 150 mm dish for 24 h. Next, crude
microsomal membranes were isolated as previ-
ously described [12] and protein content was
quantified using BCA assay (Thermo Fisher Sci-
entific). The assay contained 15 lg microsomal
protein, 100 mmol L1 Tris-HCl (pH 7.23),
0.1 mmol L1 EDTA, 1 mmol L1 dithiothreitol,
30 mmol L1 nicotinamide, 5 mmol L1 NADPH,
20 lmol L1 FAD, 30 mmol L1 glucose-6-phos-
phate, 500 lg mL1 bovine serum albumin, 2 U
glucose-6-phosphate dehydrogenase (for NADPH
regeneration), 1 lg mL1 [2H6]-desmosterol
(Avanti, 700040P) complexed to methyl-b-cy-
clodextrin and the indicated treatments (either
DMSO, amiodarone or triparanol) in a 50 lL
volume. All components except substrate [2H6]-
desmosterol were prepared whilst on ice and pre-
incubated in a 37°C water bath for 10 min to
allow binding of inhibitors to DHCR24. Next, the
[2H6]-desmosterol was added and the reaction
continued for 2 h in the 37°C water bath. The
reaction was terminated by adding 500 lL 0.1 mol
L1 NaOH. Lipids were then extracted and deriva-
tized for GC-MS analyses as described previously
[13]. Quantification of DHCR24 activity was based
on chromatographic peak areas measured for the
product, [2H6]-cholesterol, relative to the precur-
sor, [2H6]-desmosterol.
Statistical analyses
The statistical analyses were performed with
SPSS for Windows 22.0 (SPSS, Chicago, IL).
Sample size calculation was based on significance
levels (a = 0.05 and b = 0.20) and essential infor-
mation provided from a previous study [5]. Using
these estimates, the size of the required popula-
tion was appropriate. Normality and homogeneity
of variance assumptions were checked before
further analyses, and variables not normally
distributed were transformed logarithmically.
Continuous variables in the groups were com-
pared by analysis of variance, and the noncon-
tinuous variables were tested by using the chi-
square or Fisher’s exact test. Variables not nor-
mally distributed even after logarithmic transfor-
mation or nonhomogenous in variance were
tested with Kruskal–Wallis and Mann–Whitney
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U-tests. Spearman’s correlation coefficients were
calculated. A P-value of <0.05 was considered
statistically significant, whereas a P-value of
>0.05 was denoted as nonsignificant (NS). The
results are expressed as mean  SE.
Results
Clinical study
Study population and clinical characteristics
In the amiodarone (n = 126) and control (n = 110)
groups, age and BMI were similar, and 74% of the
subjects were men in both groups (Table 1). Age
and BMI were also similar between gender in the
groups. In the amiodarone group, ventricular
tachyarrhythmias were more frequent than in the
control group (P < 0.05), whereas atrial tach-
yarrhythmias were similar between the groups.
The number of cases with diagnosis of cardiomy-
opathy (CMP), either hypertrophic or dilated, or
coronary artery disease (CAD) was comparable
between the study groups as were congenital
anomalies or valvular defects (9% in the amio-
darone vs 5% in the control group (NS)) and the
frequency of type 2 diabetes (13% in the amio-
darone and 11% in the control group (NS)). In the
amiodarone and control groups, 48% and 42% of
the subjects were on statin treatment (NS), and in
both groups, 80% of the subjects on statin were
males. In both groups, one subject was on ezetim-
ibe treatment and two subjects had a combination
therapy of statin + ezetimibe. In the control group,
one and in the amiodarone group two subjects were
on low-dose corticosteroid therapy. In the amio-
darone group, the median daily dose of amiodarone
was 200 mg with a range of 100–400 mg. No signs
of thyroid, pulmonary or liver toxicity were
observed in the patients at the time of our study.
Serum lipids
We measured cholesterol, noncholesterol sterols
and triglycerides in the patients’ sera. The ratios to
Table 1. Demographics, main clinical characteristics, serum cholesterol, triglycerides and noncholesterol sterols in the study
population
Variable Control group (n = 110) Amiodarone group (n = 126)
Gender, M/F, n 81/29 93/33
Age, years 60.5  1.0 61.9  0.9
Body mass index, kg/m2 28.0  0.4 28.0  0.4
Ventricular tachyarrhythmias, % 12 25*
Atrial tachyarrhythmias, % 68 75
CMP or CAD, % 25 37
Statin treatment, yes/no, n 46/64 61/65
Serum cholesterol, mmol/L 4.58 (2.10–9.40) 4.41 (1.54–7.98)
Serum triglycerides, mmol/L 1.30 (0.44–6.11) 1.16 (0.51–6.47)
Cholesterol precursors
Squalenea 13 (4–122) 12 (3–51)
Zymostenola 16 (4–38) 37 (10–182)*
Desmosterola 94 (37–164) 696 (171–3107)*
Lathosterola 103 (9–291) 50 (7–266)*
Plant sterols and cholestanol
Campesterola 217 (61–827) 269 (99–986)
Stigmasterola 10 (5–29) 12 (5–34)*
Sitosterola 124 (35–485) 162 (59–626)
Avenasterola 38 (17–106) 45 (23–146)
Cholestanola 146 (60–266) 181 (60–367)*
Mean  SE, median (range), n, %. In the analysis of the lipids and sterols, statin treatment was used as a covariate.
CAD, coronary artery disease; CMP, cardiomyopathy.
a102µmol/mmol cholesterol.
*Significantly different from control subjects.
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cholesterol of serum cholesterol precursors are
markers of cholesterol synthesis, whilst plant
sterols and cholestanol are markers of cholesterol
absorption efficiency [14,15]. Statin treatment was
taken as a covariate in all serum lipid analyses.
The concentrations of serum total cholesterol and
triglycerides did not differ significantly between the
study groups (Table 1), reversing our previous
finding of elevated serum triglyceride concentra-
tions by amiodarone in a pilot study (5). Neither
gender nor the low-dose corticosteroid therapy had
any effect on serum cholesterol, triglycerides or
noncholesterol sterols in the groups.
Of the serum cholesterol precursors, desmosterol
and zymostenol were ~7- and ~2-fold higher and
lathosterol 50% lower, on average, in the amio-
darone than in the control group (P < 0.001 for all;
Table 1). Serum desmosterol correlated with the
daily amiodarone dose (r = 0.365, P < 0.001), but
was independent of age, gender, BMI, lipid-lower-
ing treatment or the type of cardiac disease in the
amiodarone-treated patients.
The moderate increase in serum zymostenol,
already observed in our previous study (5), indi-
cates that amiodarone also interfered with the
Kandutsch–Russell saturated sterol side chain
pathway. This can be explained by the in vitro
observation that amiodarone inhibits the activity of
D8–D7 isomerase (also known as EBP), blocking
the conversion of zymostenol to lathosterol16 and,
in fact, serum lathosterol was lowered by amio-
darone (Table 1). Of the cholesterol absorption
markers, serum stigmasterol and cholestanol were
elevated in the amiodarone compared with the
control group. In spite of these interferences,
serum cholesterol precursors correlated signifi-
cantly inversely with serum absorption markers
in the amiodarone and control groups (e.g. lathos-
terol vs. campesterol r = 0.455, P < 0.001 in the
amiodarone and r = 0.436, P < 0.001 in the con-
trol group), as well as in both groups without and
with statin treatment, suggesting intact cholesterol
homeostatic regulation in all groups.
Statin treatment affected serum cholesterol and
the noncholesterol sterols alike in the amiodarone
and the control groups. Thus, serum cholesterol
and the cholesterol precursors were lower and the
plant sterols and cholestanol higher in
statin + than statin- subjects in both groups, as
shown for serum cholesterol, desmosterol and
campesterol in Fig. 1. In fact, the plant sterols
and cholestanol were even higher in the
statin + amiodarone than statin + control group,
as shown for campesterol in Fig. 1.
In the amiodarone group, we had access to serum
samples taken before and during amiodarone
Fig. 1 Serum cholesterol concentration and the ratios to cholesterol of desmosterol and campesterol in subjects without
(S) and with (S+) statin treatment in the control (n = 110, S  n = 64, S + n = 46) and amiodarone (n = 126, S  n = 65,
S + n = 61) groups. Mean  SE. *significantly different from S  subjects, ‡significantly different from S + control subjects.
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treatment in five subjects. In each case, serum
desmosterol levels were elevated during amio-
darone treatment, with the increase of desmosterol
ranging from 297 to 1071 102 µmol mmol1
cholesterol (Fig. 2).
Effect of amiodarone on sterol levels in human cells
To analyse if amiodarone or its major metabolite
in vivo DEA affects cellular sterol synthesis, we
cultivated human A431 cells in lipoprotein-defi-
cient serum (to increase endogenous cellular
cholesterol synthesis) in the presence of amio-
darone or DEA. For comparison, we generated
A431 cells from which the enzyme converting
desmosterol to cholesterol, DHCR24, was knocked
out using CRISPR/Cas9 gene editing (DHCR24-KO
cells). We found that amiodarone and DEA effec-
tively increased cellular desmosterol levels and
concomitantly reduced cholesterol levels (Fig. 3),
suggesting that both compounds inhibit DHCR24
in cells. In addition, zymosterol and zymostenol
accumulated in amiodarone or DEA treated cells.
DHCR24-KO cells exhibited a pronounced accu-
mulation of desmosterol but not zymosterol or
zymostenol (Fig. 3), indicating that accumulation
of the latter two sterols is not secondary to
DHCR24 inhibition. Rather, amiodarone and DEA
also partially blocked EBP (D8–D7 isomerase)
activity, in agreement with previous findings [16].
Effect of amiodarone on DHCR24 enzyme activity
To test if amiodarone directly inhibits DHCR24, we
set up an in vitro assay. As a proof-of-principle, we
first tested amiodarone versus an established
inhibitor of DHCR24, triparanol, in cell culture
using CHO-7 stable cells that express human
DHCR24 (CHO-DHCR24-V5) [11]. Cells cultivated
in lipoprotein-deficient serum were incubated with
deuterated desmosterol for 4 h. We found that both
amiodarone and triparanol inhibited DHCR24
activity in cell culture (Fig. 4a and b), demon-
strated by the higher ratio of [2H6]-desmosterol to
[2H6]-cholesterol in triparanol and amiodarone-
treated cells (Fig. 4a, bottom panels), compared to
DMSO control (Fig. 4a, top right). Unlabelled cells
were included to distinguish peaks from cellular
endogenous cholesterol and desmosterol from their
deuterated counterparts (Fig. 4a, top left). To test if
amiodarone directly inhibits DHCR24, we isolated
microsomes from these cells and performed an
in vitro enzyme activity assay. This demonstrated
that amiodarone directly inhibits the activity of
DHCR24 (Fig. 4c) across two concentrations.
Discussion
This study shows that in cardiac patients amio-
darone increased the levels of the circulating choles-
terol precursors, desmosterol and zymostenol ~7-
and ~2-fold anddecreased serum lathosterol level to
a half, on average, irrespective of gender, age, BMI,
or primary cardiac or other diseases, or the use of
lipid-lowering drugs. We have previously demon-
strated that amiodarone markedly elevated serum
levels of desmosterol and to a lesser extent zymos-
tenol in a limited number of subjects with inflam-
matory cardiac disease [5]. These findings were
confirmed and expanded in the present larger,
controlled and well-matched study. Amiodarone
seemed to interfere with both Bloch and Kan-
dutsch–Russell cholesterol synthesis pathways.
Regarding the basic mechanisms, we revealed that
amiodarone results in desmosterol accumulation in
cultured human cells and that the compound
directly inhibits the DHCR24 enzyme activity in
microsomal membranes. Moreover, the increase in
zymostenol was not secondary to DHCR24 inhibi-
tion, but rather amiodarone and DEA appeared to
partially block D8–D7 isomerase activity, in keeping
with previous findings [16].
Paradoxically, elevated serum desmosterol and
zymostenol levels reflect upregulated whilst low-
ered serum lathosterol reflects downregulated
whole-body cholesterol synthesis, as verified in
different populations both at baseline and during
lipid-lowering drug treatments [14,15,17]. It is
possible that blocking the conversion of zymostenol
to lathosterol by amiodarone resulted in low
Fig. 2 Serum desmosterol to cholesterol ratio before
(Amiodarone ) and with amiodarone treatment (Amio-
darone +) in five subjects in the amiodarone group.
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lathosterol levels in vivo. Another possibility is that
high desmosterol per se interfered with cholesterol
homeostasis. In fact, desmosterol is a ligand for
liver X receptor (LXR), and inhibits the activation of
sterol response element-binding protein-2 (SREBP-
2), thereby downregulating cholesterol synthesis
[18,19]. However, the effect of amiodarone on LXR
and SREBP-2 would require formal investigation.
Due to the increase of some but decrease of other
cholesterol synthesis markers, it was not straight
forward to determine the effect of amiodarone on
whole-body cholesterol synthesis. However, ele-
vated stigmasterol and cholestanol levels in the
amiodarone group suggested increased cholesterol
absorption efficiency. According to the reciprocal
regulation of cholesterol synthesis and absorption
[20], which, importantly, was intact in the amio-
darone group, amiodarone most likely upregulated
intestinal cholesterol absorption whilst
downregulating cholesterol synthesis. The ten-
dency to steady state in human cholesterol meta-
bolism explains the similar cholesterol
concentrations in the amiodarone and control
groups, unlike in the in vitro studies, where cellular
cholesterol was decreased by amiodarone.
Regarding the combination of amiodarone with
statins, several interesting observationsweremade.
First, in the amiodarone group, the statin-induced
inhibition of HMGCR was clearly only partial, since
we still observed the desmosterol accumulation in
this group. Metabolic studies have demonstrated
that the statin-induced reduction in whole-body
cholesterol synthesis is ~40% [21], but thismay vary
between statins and dosage. Second, a more signif-
icant upregulation of the absorption markers with
the combination of statin + amiodarone treatment
compared to statin alone may result from the fact
that amiodarone increases the circulating
Fig. 3 Effects of amiodarone and DEA on cellular sterol profile. (a) Sterol profiles of A431 cells treated with the indicated
drug (WT = wild-type A431 cells treated with solvent only) for the final 48 h of the 3-day LPDS starvation. Two independent
measurements for each. (b) Schematic cartoon of the findings in A with respect to the cholesterol synthesis pathway.
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concentration of statins by inhibiting CYP3A4; con-
sequently, cholesterol absorption increases [17]. In
addition, it is possible that blocking cholesterol
synthesis at two steps (early and late) might give an
enhanced compensatory increase in cholesterol and
sterol absorption in general, and this may con-
tribute to the similar cholesterol reductionwithboth
synthesis inhibitors vs. statin alone. During amio-
darone + statin treatment, inhibiting cholesterol
absorption with phytostanols or ezetimibe could
still lower serum cholesterol concentration. In fact,
some patients in the amiodarone group had amio-
darone + statin + ezetimibe combination therapy,
with serum cholesterol concentrations within the
goal values and without side effects (data not
shown).
As previously proposed [5], the simplest explana-
tion for the increase in serum desmosterol
observed in response to amiodarone treatment is
that this drug inhibits DHCR24, the enzyme reduc-
ing the double bond in the side chain of desmos-
terol to make cholesterol. Supporting this idea, we
observed in cell experiments that amiodarone
increased desmosterol at the expense of cholesterol
(Figs 3, 4a and b). Moreover, we found using an
isolated microsome system that amiodarone
directly inhibits DHCR24 activity to a comparable
extent as the archetypal DHCR24 inhibitor, tri-
paranol (Fig. 4c). Amiodarone and triparanol share
structural similarities [6]. In particular, they both
possess a diethylaminoethoxy side chain which
corresponds in length and general conformation to
the sterol side chain [22]. It has been proposed that
the lone electron of the nitrogen atom, which is
situated at a position analogous to C-24 of the
sterol, plays the same binding role as the D24
double bond electrons of the desmosterol substrate
[23]. Further work would be required to determine
if amiodarone and triparanol share the same
Fig. 4 Amiodarone and triparanol inhibit DHCR24 enzyme activity. (a) Chromatograms from a cell culture experiment as
proof-of-principle for DHCR24 inhibition. (b) CHO-DHCR24-V5 cells were treated with the indicated inhibitors for 48 h.
DMSO concentration was kept at 0.2% (v/v) in all conditions. Cells were labelled with [2H6]-desmosterol for 4 h and
harvested for lipid extraction to analyse [2H6]-cholesterol levels relative to [
2H6]-desmosterol levels. The [
2H6]-cholesterol to
[2H6]-desmosterol ratios were normalized so that the control condition was set to 1. (c) Microsomes from CHO-DHCR24-V5
cells were pretreated with the indicated inhibitors in an activity assay buffer in vitro for 10 min. Microsomes were then
labelled with [2H6]-desmosterol for 2 h and harvested for lipid extraction for GC-MS analyses as in b. Data are mean from
two independent experiments.
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mechanism of inhibition, which for triparanol has
been reported to be noncompetitive [24].
At therapeutic concentrations, amiodarone alters
the functions of multiple ion channels controlling
the cardiac action potential [25]. Importantly, these
are integral membrane proteins that are affected by
the surrounding lipid bilayer. Based on our results,
amiodarone modifies the sterol composition of cell
membranes, and it seems plausible that this may
contribute to the multi-target effects of the drug.
On the other hand, a major limitation of long-term
amiodarone therapy is its broad and unusual side
effect profile. The present data also open the
possibility that some of the adverse effects might
in fact result from DHCR24 inhibition. For
instance, DHCR4 inhibition can lead to cataracts
[26], a known side effect of amiodarone. However,
the amiodarone-related transient cataract is less
severe compared with that caused by triparanol
treatment. The latter develops rapidly within 3 to
19 months from starting the therapy and leading to
severe cataracts requiring operative treatment even
in middle-aged subjects without any predisposing
risk factors [27,28]. Also, the sensitivity of the
thyroid to amiodarone-induced toxicity (hypo- or
hyperthyroidism) might be linked to high levels of
DHCR24 in the thyroid: DHCR24 is upregulated by
thyroid hormones and thyroid hormone receptor
[29,30]. Pulmonary side effects might, instead, be
related to the phospholipidosis typically induced
by cationic amphiphilic drugs, rather than direct
enzyme inhibition. Regarding the liver toxicity,
amiodarone can cause nonalcoholic steatohepati-
tis [31] and interestingly, preliminary results
demonstrate that liver desmosterol accumulation
was correlated with the severity of inflammation
and steatosis [32].
Conclusions
We have demonstrated that amiodarone increased
serum desmosterol level independently of gender,
age, BMI, cardiac and other diseases, and lipid-
lowering medication. Lipid analyses in patient
samples taken before and after initiation of amio-
darone showed a systematic increase of desmos-
terol upon drug administration, strongly arguing
for a direct causal link between amiodarone and
desmosterol accumulation. Mechanistically, we
found that amiodarone resulted in desmosterol
accumulation in cultured human cells and that the
compound directly inhibited the DHCR24 enzyme
activity in microsomal membranes.
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